{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:12Z","timestamp":1786997892453,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-009333"],"award-info":[{"award-number":["INV-009333"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2021.04.026","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T01:21:14Z","timestamp":1619486474000},"page":"A12-A18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"S1","title":["The impact of disruptions caused by the COVID-19 pandemic on global polio eradication"],"prefix":"10.1016","volume":"41","author":[{"given":"Dominika A.","family":"Kalkowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"Voorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Pallansch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.F.","family":"Wassilak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Cochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Badizadegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.04.026_b0005","unstructured":"World Health Organization Global Polio Eradication Initiative. Call to action to support COVID-19 response. https:\/\/polioeradication.org\/news-post\/call-to-action-to-support-covid-19-response\/; 2020 [accessed August 20, 2020]."},{"key":"10.1016\/j.vaccine.2021.04.026_b0010","unstructured":"World Health Organization Global Polio Eradication Initiative. Polio eradication and endgame Strategic Plan (2013-2018). http:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/PEESP_EN_A4.pdf; 2013 [accessed Jun 4, 2019]."},{"key":"10.1016\/j.vaccine.2021.04.026_b0015","first-page":"934","article-title":"Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - Worldwide, 2016","volume":"65","author":"Hampton","year":"2016","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2021.04.026_b0020","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/14760584.2020.1791093","article-title":"Review of poliovirus modeling performed from 2000\u20132019 to support global polio eradication","volume":"19","author":"Thompson","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.04.026_b0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/risa.13484","article-title":"Reflections on modeling poliovirus transmission and the polio eradication endgame","volume":"41","author":"Thompson","year":"2020","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.026_b0030","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/risa.13447","article-title":"Global transmission of live polioviruses: updated integrated dynamic modeling of the polio endgame","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.026_b0035","unstructured":"World Health Organization Global Polio Eradication Initiative. Polio eradication and endgame strategic plan (2019-2023). http:\/\/polioeradication.org\/wp-content\/uploads\/2019\/05\/polio-endgame-strategy-2019-2023.pdf; 2019 [accessed Jun 4, 2019]."},{"key":"10.1016\/j.vaccine.2021.04.026_b0040","unstructured":"World Health Organization Global Polio Eradication Initiative. Strategy for the response to type 2 circulating vaccine-derived poliovirus 2020\u20132021: Addendum to the Polio eradication and endgame strategic plan (2019-2023). http:\/\/polioeradication.org\/wp-content\/uploads\/2020\/04\/Strategy-for-the-response-to-type-2-circulating-Vaccine-Derived-Poliovirus-20200406.pdf; 2020 [accessed Mar 10, 2020]."},{"key":"10.1016\/j.vaccine.2021.04.026_b0045","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/risa.12962","article-title":"Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations","volume":"38","author":"Duintjer Tebbens","year":"2018","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.026_b0050","doi-asserted-by":"crossref","unstructured":"Duintjer Tebbens RJ, Thompson KM. Evaluation of proactive and reactive proactive strategies for polio eradication activities in Pakistan and Afghanistan. Risk Anal 2019;39:389-401.","DOI":"10.1111\/risa.13194"},{"key":"10.1016\/j.vaccine.2021.04.026_b0055","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/risa.13193","article-title":"Environmental surveillance system characteristics and impacts on confidence about no undetected serotype 1 wild poliovirus circulation","volume":"39","author":"Kalkowska","year":"2019","journal-title":"Risk Anal."},{"key":"10.1016\/j.vaccine.2021.04.026_b0060","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/risa.13214","article-title":"Modeling undetected live poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan","volume":"39","author":"Kalkowska","year":"2019","journal-title":"Risk Anal."},{"key":"10.1016\/j.vaccine.2021.04.026_b0065","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/risa.13471","article-title":"Insights from modeling preventive supplemental immunization activities as a strategy to eliminate wild poliovirus transmission in Pakistan and Afghanistan","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.026_b0070","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/risa.13555","article-title":"Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.026_b0075","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/14760584.2019.1635463","article-title":"Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV)","volume":"18","author":"Thompson","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.04.026_b0080","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","article-title":"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study","volume":"394","author":"Van Damme","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.04.026_b0085","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/risa.13622","article-title":"Updated characterization of poliovirus outbreak response strategies for 2019\u20132029: Impacts of the use of novel OPV2 strains","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.026_b0090","doi-asserted-by":"crossref","unstructured":"Thompson KM, Kalkowska DA. Potential future use, costs, and value of poliovirus vaccines. Risk Anal 2020; online Jul 9. doi: 10.1111\/risa.13557.","DOI":"10.1111\/risa.13557"},{"key":"10.1016\/j.vaccine.2021.04.026_b0095","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/risa.13664","article-title":"Health and economic outcomes associated with polio vaccine policy options: 2019\u20132029","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.026_b0100","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/risa.13665","article-title":"An updated economic analysis of the Global Polio Eradication Initiative","volume":"41","author":"Thompson","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.026_b0105","first-page":"561","article-title":"Projection of costs of polio eradication compared to permanent control","volume":"221","author":"Zimmermann","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.026_b0110","unstructured":"Independent Monitoring Board of the Global Polio Eradication Initiative. How to cut a long story short, 16th Report, October 2018. Available from: http:\/\/polioeradicationorg\/wp-content\/uploads\/2018\/11\/20181105-16th-IMB-Report-FINALpdf, accessed 27 August 2020; 2018."},{"key":"10.1016\/j.vaccine.2021.04.026_b0115","unstructured":"Independent Monitoring Board of the Global Polio Eradication Initiative. The art of survival: independent monitoring board of the Global Polio Eradication Initiative, 17th Report, November 2019. Available from: http:\/\/wwwpolioeradicationorg\/Portals\/0\/Document\/Aboutus\/Governance\/IMB\/10IMBMeeting\/10IMB_Report_ENpdf, accessed 27 August 2020; 2019."},{"key":"10.1016\/j.vaccine.2021.04.026_b0120","unstructured":"Independent Monitoring Board of the Global Polio Eradication Initiative. The new normal: finding the path back to eradication in the time of coronavirus, 18th Report, December 2020. Available from: http:\/\/polioeradicationorg\/wp-content\/uploads\/2020\/08\/20200816-IMB-18th-Report-FINALpdf, accessed 27 August 2020; 2020."},{"issue":"7","key":"10.1016\/j.vaccine.2021.04.026_b0125","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1016\/S2214-109X(20)30229-1","article-title":"Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study","volume":"8","author":"Roberton","year":"2020","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.vaccine.2021.04.026_b0130","doi-asserted-by":"crossref","unstructured":"Abbas K, Procter SR, van Zandvoort K, Clark A, Funk S, Mengistu T, et al. Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit&#x2013;risk analysis of health benefits versus excess risk of SARS-CoV-2 infection. Lancet Glob Health 2020, 8,(10):e1264 - e1272.","DOI":"10.1016\/S2214-109X(20)30308-9"},{"key":"10.1016\/j.vaccine.2021.04.026_b0135","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1539-6924.2012.01891.x","article-title":"Modeling population immunity to support efforts to end the transmission of live polioviruses","volume":"33","author":"Thompson","year":"2013","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.026_b0140","unstructured":"World Bank. World Bank analytical classifications - calendar year 2017 GNI per capita in US$ (Atlas methodology). Available from: http:\/\/databank.worldbank.org\/data\/download\/site-content\/OGHIST.xls; 2019 [accessed June 4, 2019]."},{"key":"10.1016\/j.vaccine.2021.04.026_b0145","unstructured":"World Health Organization. World schedule as of 2018\/July\/11. Available from: http:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/schedules; 2019 [accessed July 19, 2019]."},{"key":"10.1016\/j.vaccine.2021.04.026_b0150","doi-asserted-by":"crossref","unstructured":"Duintjer Tebbens RJ, Pallansch MA, Wassalik SGF, Cochi SL, Thompson KM. An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infectious Dis 2015;15. doi: 10.1186\/s12879-015-1112-8.","DOI":"10.1186\/s12879-015-1112-8"},{"key":"10.1016\/j.vaccine.2021.04.026_b0155","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12879-016-1537-8","article-title":"Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of potential non-synchronous cessation","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.026_b0160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12879-016-1536-9","article-title":"Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.026_b0165","unstructured":"World Bank. International tourism number of departures. Available from: https:\/\/data.worldbank.org\/indicator\/ST.INT.DPRT; 2020 [accessed Oct 5, 2020]."},{"key":"10.1016\/j.vaccine.2021.04.026_b0170","unstructured":"University of Oxford. Our World in Data: International travel controls during the COVID-19 pandemic. Available from: https:\/\/ourworldindata.org\/grapher\/international-travel-covid; 2020 [accessed July 17, 2020]."},{"key":"10.1016\/j.vaccine.2021.04.026_b0175","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1093\/infdis\/jix128","article-title":"Lessons from globally-coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes","volume":"216","author":"Thompson","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.026_b0180","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14760584.2018.1506333","article-title":"Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine","volume":"17","author":"Duintjer Tebbens","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.04.026_b0185","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1016\/j.vaccine.2010.04.001","article-title":"Optimal vaccine stockpile design for an eradicated disease: application to polio","volume":"28","author":"Duintjer Tebbens","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.026_b0190","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14760584.2017.1322514","article-title":"Poliovirus vaccination during the endgame: insights from integrated modeling","volume":"16","author":"Duintjer Tebbens","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.04.026_b0195","doi-asserted-by":"crossref","DOI":"10.1080\/14760584.2021.1891888","article-title":"Hypothetical emergence of poliovirus in 2020: 1. Consequences of policy decisions to respond using nonpharmaceutical interventions","author":"Thompson","year":"2021","journal-title":"Expert Rev Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21004734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21004734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:53Z","timestamp":1759404293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21004734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":39,"alternative-id":["S0264410X21004734"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.026","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of disruptions caused by the COVID-19 pandemic on global polio eradication","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}